Subtype
Primary Central Nervous System Neoplasm
CI-CAN-00001432Explore in graph →
Non-malignant957 active trials5 approved drugs175 evidence items
- NCIt
- C102871
Loading cancer entity…
Subtype
CI-CAN-00001432Explore in graph →
Clinical trials
3,294 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04049669 | Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG | active not recruiting | Phase 2 | 130 | Theodore S. JohnsonOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04221503 | Niraparib/TTFields in GBM | active not recruiting | Phase 2 | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05211336 |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System |
| active not recruiting |
| Phase 1 |
| 14 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Jan 8, 2026 |
| clinicaltrials |
| NCT02358187 | A Vaccine Trial for Low Grade Gliomas | recruiting | Phase 2 | 25 | James FelkerOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03743662 | Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma | active not recruiting | Phase 2 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05049148 | Platelets Activation in Brain Neoplasms(Platon) | recruiting | N/A | 50 | Fondation Ophtalmologique Adolphe de RothschildNETWORK | 1 | Jan 5, 2026 | clinicaltrials |
| NCT04959500 | Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06717295 | The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling(CCANED-CIPHER) | recruiting | — | 6,000 | Javier ToledoINDUSTRY | 3 | Jan 2, 2026 | clinicaltrials |
| NCT06829173 | Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas | recruiting | Early Phase 1 | 39 | NYU Langone HealthOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07093814 | A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma | recruiting | Phase 1 / Phase 2 | 42 | Guangzhou Virotech Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors(VARTUTRACE) | recruiting | Early Phase 1 | 32 | Var2 PharmaceuticalsINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07306299 | A Phase I Clinical Trial of a mRNA Vaccine for Recurrent or Progressive High-grade Glioma | recruiting | Phase 1 | 10 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT04116411 | A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients(VIGAS2) | active not recruiting | Phase 2 | 220 | Cecilia Soderberg-NauclerOTHER | 2 | Dec 22, 2025 | clinicaltrials |
| NCT05423210 | Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme | recruiting | Early Phase 1 | 12 | Stony Brook UniversityOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT04691960 | A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging | active not recruiting | Phase 2 | 18 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT06468176 | Efficacy of a Mixed Distancial Neuropsychological Rehabilitation Program in Patients With Grade 2 or 3 Diffuse Glioma(FREEDOME) | recruiting | N/A | 187 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07145047 | Clinical Study of Oncolytic Virus in Glioblastoma | recruiting | Phase 1 / Phase 2 | 20 | Mianyang Central HospitalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | recruiting | Phase 1 | 102 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04543201 | Telehealth Visits to Discuss Advanced Directives for Patients Newly Diagnosed With High Grade Glioma | recruiting | N/A | 50 | University of RochesterOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07291102 | Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma | not yet recruiting | Phase 3 | 96 | Nationwide Children's HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03500991 | HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors | active not recruiting | Phase 1 | 10 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05259605 | Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification | recruiting | — | 1,650 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Dec 17, 2025 | clinicaltrials |
| NCT05976490 | NeuroPathways Intervention for Brain Tumor Patients | recruiting | N/A | 50 | Massachusetts General HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07062627 | Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma | recruiting | Phase 2 | 12 | Hyungwoo ChoOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05686798 | Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. | recruiting | Phase 1 | 18 | Henry Ford Health SystemOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06898684 | Medulloblastoma Online Video-based Exercise Pilot Study(MOVE) | recruiting | N/A | 15 | Aron OnerupOTHER_GOV | 2 | Dec 16, 2025 | clinicaltrials |
| NCT07285525 | Accelerating Motor Recovery in Glioma Patients Using Postoperative nrTMS | active not recruiting | N/A | 43 | Beijing Neurosurgical InstituteOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07286903 | Fluorescence Enhanced Stereotactic Surgery (FESS)(FESS) | recruiting | — | 20 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07286929 | Evaluation of the Variation Over Time of Visuospatial Deficit in Patients With Parietal Lobe Glioma(neGLIO) | recruiting | — | 40 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05798507 | Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma | active not recruiting | Early Phase 1 | 14 | Emory UniversityOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT01358058 | Proton Radiation Therapy for Gliomas | active not recruiting | N/A | 63 | Massachusetts General HospitalOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05956821 | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | recruiting | Phase 1 / Phase 2 | 20 | University of MiamiOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07077616 | Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.(TAMAVAQTM) | recruiting | Early Phase 1 | 29 | Biogenea Pharmaceuticals Ltd.INDUSTRY | 1 | Dec 8, 2025 | clinicaltrials |
| NCT03212742 | Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients(OLA-TMZ-RTE-01) | active not recruiting | Phase 1 / Phase 2 | 91 | Centre Francois BaclesseOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05553041 | 18F-Fluciclovine PET-MRI in High-grade Glioma | recruiting | Early Phase 1 | 30 | Children's Hospital of PhiladelphiaOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07263711 | Prospective Real-World Study of Pathology AI for Glioma Molecular Prediction | recruiting | — | 2,000 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06209567 | A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors | active not recruiting | Early Phase 1 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05990244 | Magnetic Resonance Elastography in Glioma: Exploring Tumor Stiffness and Adhesion | recruiting | N/A | 100 | Shengjing HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06964815 | Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients(STRONG) | recruiting | N/A | 110 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT03687957 | rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide | active not recruiting | Phase 1 / Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT03718767 | Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | active not recruiting | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770544 | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06988475 | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07244666 | Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma | not yet recruiting | Early Phase 1 | 36 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03233152 | A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.(GlitIpNi) | active not recruiting | Phase 1 / Phase 2 | 110 | Universitair Ziekenhuis BrusselOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04081701 | 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.(DOMINO-START) | recruiting | Phase 4 | 200 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04945148 | Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide(OPTIMUM) | recruiting | Phase 2 | 640 | Hopital FochOTHER | 2 | Nov 21, 2025 | clinicaltrials |
| NCT06930846 | HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)(HOBSCOTCH-CA) | recruiting | N/A | 125 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04250922 | LAM561 With RT and TMZ for Adults With Glioblastoma(CLINGLIO) | active not recruiting | Phase 2 / Phase 3 | 144 | Laminar PharmaceuticalsINDUSTRY | 5 | Nov 20, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 8, 2026source: clinicaltrials